Granted Patent
B2
US 12,391,918 · App. 17/971,677 · Granted Aug 19, 2025
Media for culturing stem cells
C12N5/0606C12N5/0018C12N5/0037C12N5/0043C12N5/0056C12N5/0602C12N5/0603C12N2500/90C12N2500/98C12N2501/115C12N2501/15C12N2501/23C12N2501/2306C12N2506/02C12N2533/52
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.
Claims (29)
1. A method of generating lineage-specific cells from primate embryonic stem cells, the method comprising:
(a) culturing the primate embryonic stem cells in a protein carrier-free culture medium comprising basic fibroblast growth factor (bFGF) and at least one factor selected from the group consisting of: transforming growth factor beta-3 (TGFβ3) isoform, transforming growth factor beta-1 (TGFβ1) isoform and IL6RIL6 chimera, wherein said IL6RIL6 chimera comprises amino acids 112-355 of SEQ ID NO: 32,
to thereby obtain expanded, undifferentiated embryonic stem cells;
(b) subjecting said expanded, undifferentiated primate embryonic stem cells to culturing conditions suitable for differentiating and/or expanding lineage specific cells;
thereby generating the lineage-specific cells from the primate embryonic stem cells.
2. A method of generating embryoid bodies from primate embryonic stem cells, the method comprising:
(a) culturing the primate embryonic stem cells in a protein carrier-free culture medium comprising basic fibroblast growth factor (bFGF) and at least one factor selected from the group consisting of: transforming growth factor beta-3 (TGFβ3) isoform, transforming growth factor beta-1 (TGFβ1) isoform and IL6RIL6 chimera, wherein said IL6RIL6 chimera comprises amino acids 112-355 of SEQ ID NO: 32,
to thereby obtain expanded, undifferentiated embryonic stem cells; and
(b) subjecting said expanded, undifferentiated embryonic stem cells to culturing conditions suitable for differentiating said primate embryonic stem cells to embryoid bodies;
thereby generating the embryoid bodies from the primate embryonic stem cells.
3. A method of generating lineage-specific cells from primate embryonic stem cells, the method comprising:
culturing the primate embryonic stem cells in a protein carrier-free culture medium comprising basic fibroblast growth factor (bFGF) and at least one factor selected from the group consisting of: transforming growth factor beta-3 (TGFβ3) isoform, transforming growth factor beta-1 (TGFβ1) isoform and IL6RIL6 chimera, wherein said IL6RIL6 chimera comprises amino acids 112-355 of SEQ ID NO: 32, to thereby obtain expanded, undifferentiated primate embryonic stem cells;
(b) subjecting said expanded, undifferentiated primate embryonic stem cells to culturing conditions suitable for differentiating said expanded, undifferentiated embryonic stem cells to embryoid bodies; and
(c) subjecting cells of said embryoid bodies to culturing conditions suitable for differentiating and/or expanding lineage specific cells;
thereby generating the lineage-specific cells from the primate embryonic stem cells.
4. The method of claim 1 , wherein said culture medium is serum-free.
5. The method of claim 1 , wherein said culture medium further comprises insulin, transferrin, selenium and a lipid mixture.
6. The method of claim 1 , wherein said culturing is effected in xeno-free culturing conditions.
7. The method of claim 1 , wherein said culturing is effected in a suspension culture.
8. The method of claim 1 , wherein said culturing is effected on a feeder-layer free matrix.
9. The method of claim 1 , wherein said culturing is effected on feeder cells.
10. The method of claim 1 , wherein said at least one factor is said TGFβ3 isoform, and wherein the culture medium which comprises said TGFβ3 isoform is serum-free, animal contaminant-free, feeder-free and protein carrier-free.
11. The method of claim 1 , wherein said at least one factor is said IL6RIL6 chimera and wherein the culture medium which comprises said IL6RIL6 chimera further comprises ascorbic acid.
12. The method of claim 1 , wherein said bFGF is at a concentration of at least 2 ng/ml.
13. The method of claim 1 , wherein said at least one factor is said TGFβ3 isoform, and wherein said TGFβ3 is at a concentration of at least 0.5 ng/ml.
14. The method of claim 1 , wherein said at least one factor is said TGFβ3 isoform, wherein said TGFβ3 is at a concentration of at least 0.5 ng/ml and wherein said bFGF is at a concentration of at least 2 ng/ml.
15. The method of claim 1 , wherein said at least one factor is said IL6RIL6 chimera, and wherein said IL6RIL6 chimera is provided at a concentration of at least 25 ng/ml.
16. The method of claim 11 , wherein said ascorbic acid is at a concentration of 500 ng/ml±10%.
17. The method of claim 1 , wherein said primate embryonic stem cells are human embryonic stem cells.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 4, 2022
From: AMIT, MICHAL; ITSKOVITZ-ELDOR, JOSEPH
To: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
Reel/Frame 061652/0890 →
Continuity (7)
Division
11991077
Provisional Application
60834795
· Aug 2, 2006
Provisional Application
60711668
· Aug 29, 2005
References Cited (309)
US 5418159A
· Gough et al.
· 1995
[cited by applicant]
US 6107543A
· Sims et al.
· 2000
[cited by applicant]
US 6245566B1
· Gearhart et al.
· 2001
[cited by applicant]
US 6576464B2
· Gold et al.
· 2003
[cited by applicant]
US 7250294B2
· Carpenter et al.
· 2007
[cited by applicant]
US 7413902B2
· Bodnar et al.
· 2008
[cited by applicant]
US 7413904B2
· Gold et al.
· 2008
[cited by applicant]
US 7432104B2
· Mitalipova et al.
· 2008
[cited by applicant]
US 7452718B2
· Gold et al.
· 2008
[cited by applicant]
US 7455983B2
· Xu et al.
· 2008
[cited by applicant]
US 7473555B2
· Mandalam et al.
· 2009
[cited by applicant]
US 7504257B2
· Reubinoff et al.
· 2009
[cited by applicant]
US 7560281B2
· Carpenter et al.
· 2009
[cited by applicant]
US 7638328B2
· Eriksson et al.
· 2009
[cited by applicant]
US 7641897B2
· Weissman et al.
· 2010
[cited by applicant]
US 7824670B2
· Haggiag et al.
· 2010
[cited by applicant]
US 7851167B2
· Xu
· 2010
[cited by applicant]
US 7892835B2
· Akaike et al.
· 2011
[cited by applicant]
US 7897389B2
· Gold et al.
· 2011
[cited by applicant]
US 7951591B2
· Robl et al.
· 2011
[cited by applicant]
US 8067233B2
· Totey et al.
· 2011
[cited by applicant]
US 8252585B2
· Carpenter
· 2012
[cited by applicant]
US 8252586B2
· Carpenter et al.
· 2012
[cited by applicant]
US 8318486B2
· Amit et al.
· 2012
[cited by applicant]
US 8563311B2
· Amit et al.
· 2013
[cited by applicant]
US 8597947B2
· Reubinoff
· 2013
[cited by applicant]
US 8637311B2
· Mandalam et al.
· 2014
[cited by applicant]
US 8697444B2
· Schoonjans
· 2014
[cited by applicant]
US 8722405B2
· Tryggvason et al.
· 2014
[cited by applicant]
US 9040297B2
· Amit et al.
· 2015
[cited by applicant]
US 9404079B2
· Amit et al.
· 2016
[cited by applicant]
US 9834749B2
· Amit et al.
· 2017
[cited by applicant]
US 20020127715A1
· Benvenisty et al.
· 2002
[cited by applicant]
US 20020168763A1
· Yan et al.
· 2002
[cited by applicant]
US 20030153082A1
· Bhatia
· 2003
[cited by applicant]
US 20030211603A1
· Earp et al.
· 2003
[cited by applicant]
US 20030224411A1
· Stanton et al.
· 2003
[cited by applicant]
US 20040077985A1
· Rudd
· 2004
[cited by applicant]
US 20040110286A1
· Bhatia
· 2004
[cited by applicant]
US 20040137612A1
· Baksh et al.
· 2004
[cited by applicant]
US 20040191901A1
· Assady et al.
· 2004
[cited by applicant]
US 20040229350A1
· Strelchenko et al.
· 2004
[cited by applicant]
US 20050032207A1
· Wobus et al.
· 2005
[cited by applicant]
US 20050095703A1
· Semb et al.
· 2005
[cited by applicant]
US 20050095708A1
· Pera et al.
· 2005
[cited by applicant]
US 20050101014A1
· Keirstead et al.
· 2005
[cited by applicant]
US 20050118713A1
· Strelchenko et al.
· 2005
[cited by applicant]
US 20050153444A1
· Mandalam et al.
· 2005
[cited by applicant]
US 20050153445A1
· Mandalam et al.
· 2005
[cited by applicant]
US 20050164383A1
· Reubinoff et al.
· 2005
[cited by applicant]
US 20050210537A1
· Dominko et al.
· 2005
[cited by applicant]
US 20050214938A1
· Gold et al.
· 2005
[cited by applicant]
US 20050227352A1
· Xie
· 2005
[cited by applicant]
US 20060057720A1
· Xu et al.
· 2006
[cited by applicant]
US 20060134636A1
· Stanton et al.
· 2006
[cited by applicant]
US 20060182724A1
· Riordan
· 2006
[cited by applicant]
US 20060252150A1
· Cheng
· 2006
[cited by applicant]
US 20070053890A1
· Rosic-Kablar et al.
· 2007
[cited by applicant]
US 20070248945A1
· McLaughlin et al.
· 2007
[cited by applicant]
US 20070249044A1
· Desai et al.
· 2007
[cited by applicant]
US 20070280989A1
· Shahar et al.
· 2007
[cited by applicant]
US 20070298453A1
· Murdoch et al.
· 2007
[cited by applicant]
US 20080070303A1
· West et al.
· 2008
[cited by applicant]
US 20080076176A1
· Dominko et al.
· 2008
[cited by applicant]
US 20080182328A1
· Snyder et al.
· 2008
[cited by applicant]
US 20080241919A1
· Parsons et al.
· 2008
[cited by applicant]
US 20080274125A1
· Guehenneux
· 2008
[cited by applicant]
US 20080311607A1
· Geng et al.
· 2008
[cited by applicant]
US 20090029461A1
· Choo et al.
· 2009
[cited by applicant]
US 20090104695A1
· Shushan et al.
· 2009
[cited by applicant]
US 20090136559A1
· Athanasiou et al.
· 2009
[cited by applicant]
US 20090155218A1
· Hayek et al.
· 2009
[cited by applicant]
US 20100047906A1
· Totey et al.
· 2010
[cited by applicant]
US 20100068806A1
· Laine et al.
· 2010
[cited by applicant]
US 20100069251A1
· Kim et al.
· 2010
[cited by applicant]
US 20100093091A1
· Reubinoff et al.
· 2010
[cited by applicant]
US 20100120145A1
· Brunner et al.
· 2010
[cited by applicant]
US 20110039332A1
· Sakurada et al.
· 2011
[cited by applicant]
US 20110311977A1
· Mandal et al.
· 2011
[cited by applicant]
US 20130102023A1
· Smith et al.
· 2013
[cited by applicant]
US 20130130375A1
· Rudy-Reil
· 2013
[cited by applicant]
US 20130316445A1
· Beardsley et al.
· 2013
[cited by applicant]
AU 2000072431
· 2001
[cited by applicant]
AU 2001011128
· 2001
[cited by applicant]
AU 2002237681
· 2002
[cited by applicant]
AU 2002313670
· 2003
[cited by applicant]
AU 2004294835
· 2005
[cited by applicant]
AU 2009213101
· 2009
[cited by applicant]
AU 2014201623
· 2014
[cited by applicant]
CA 2248555
· 1997
[cited by applicant]
CA 2409698
· 2001
[cited by applicant]
CA 2434760
· 2002
[cited by applicant]
CA 2447015
· 2002
[cited by applicant]
CA 2451486
· 2003
[cited by applicant]
CA 2453068
· 2003
[cited by applicant]
CA 2453438
· 2003
[cited by applicant]
CA 2468335
· 2003
[cited by applicant]
CA 2469483
· 2003
[cited by applicant]
CA 2470539
· 2003
[cited by applicant]
CA 2508880
· 2004
[cited by applicant]
CA 2524611
· 2004
[cited by applicant]
CA 2559854
· 2005
[cited by applicant]
CA 2573437
· 2006
[cited by applicant]
CA 2640644
· 2013
[cited by applicant]
EP 1809739
· 2007
[cited by applicant]
EP 2267116
· 2010
[cited by applicant]
GB 2379447
· 2003
[cited by applicant]
GB 2392674
· 2004
[cited by applicant]
GB 2393733
· 2004
[cited by applicant]
GB 2393734
· 2004
[cited by applicant]
GB 2394723
· 2004
[cited by applicant]
GB 2427873
· 2007
[cited by applicant]
GB 2431165
· 2007
[cited by applicant]
HK 1075673
· 2009
[cited by applicant]
HK 1103106
· 2009
[cited by applicant]
HK 1055765
· 2010
[cited by applicant]
IL 141742
· 2002
[cited by applicant]
IL 152741
· 2003
[cited by applicant]
IL 159324
· 2004
[cited by applicant]
IL 159578
· 2004
[cited by applicant]
IL 159580
· 2004
[cited by applicant]
IL 160403
· 2004
[cited by applicant]
IL 177324
· 2006
[cited by applicant]
IL 178006
· 2006
[cited by applicant]
IL 180447
· 2007
[cited by applicant]
WO WO9733995
· 1997
[cited by applicant]
WO WO9901763
· 1999
[cited by applicant]
WO WO9902552
· 1999
[cited by applicant]
WO WO9920740
· 1999
[cited by applicant]
WO WO9920741
· 1999
[cited by applicant]
WO WO00070021
· 2000
[cited by applicant]
WO WO0231123
· 2002
[cited by applicant]
WO WO0244343
· 2002
[cited by applicant]
WO WO02086104
· 2002
[cited by applicant]
WO WO03000868
· 2003
[cited by applicant]
WO WO03004605
· 2003
[cited by applicant]
WO WO03006950
· 2003
[cited by applicant]
WO WO03014359
· 2003
[cited by applicant]
WO WO03020920
· 2003
[cited by applicant]
WO WO03050249
· 2003
[cited by applicant]
WO WO03050250
· 2003
[cited by applicant]
WO WO03095628
· 2003
[cited by applicant]
WO WO2004031369
· 2004
[cited by applicant]
WO WO2004044158
· 2004
[cited by applicant]
WO WO2004050826
· 2004
[cited by applicant]
WO WO2004055155
· 2004
[cited by applicant]
WO WO2004055155A2
· 2004
[cited by examiner]
WO WO2004111210
· 2004
[cited by applicant]
WO WO2005065354
· 2005
[cited by applicant]
WO WO2006017370
· 2006
[cited by applicant]
WO WO2006020889
· 2006
[cited by applicant]
WO WO2006029198A2
· 2006
[cited by examiner]
WO WO2006070370
· 2006
[cited by applicant]
WO WO2007002086
· 2007
[cited by applicant]
WO WO2007002210
· 2007
[cited by applicant]
WO WO2007026353
· 2007
[cited by applicant]
WO WO2007122233
· 2007
[cited by applicant]
WO WO2008007082
· 2008
[cited by applicant]
WO WO2008015682
· 2008
[cited by applicant]
WO WO2008054819
· 2008
[cited by applicant]
WO WO2008148105
· 2008
[cited by applicant]
Official Action Dated Nov. 16, 2023 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/178,279. (82 pages).
[cited by applicant]
Kassem et al. “Mesenchymal Stem Cells: Cell Biology and Potential Use in Therapy”, Basic & Clinical Pharmacology & Toxicology, 95(5): 209-214, 2004.
[cited by applicant]
Pan et al. “Stem Cell Pluripotency and Trascription Factor Oct4”, Cell Research, 12(5-6):321-329, 2002.
[cited by applicant]
St. John et al. “Analysis and Isolation of Embryonic Mammalian Neurons by Fluorescence-Activated Cell Sorting”, The Journal of Neuroscience, 6(5): 1492-1512, May 1986.
[cited by applicant]
University of Michigan Medical School “Embryonic Period (Weeks 3-8)”, Anatomy, University of Michigan Medical School, pp. 1-5, 1999.
[cited by applicant]
Notice of Allowance Dated Apr. 8, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/178,279. (8 pages).
[cited by applicant]
Advisory Action Before the Filing of an Appeal Brief Dated Jul. 6, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/720,853. (4 pages).
[cited by applicant]
Advisory Action Before the Filing of an Appeal Brief Dated Jul. 9, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/309,817.
[cited by applicant]
Applicant-Initiated Interview Summary Dated Jan. 11, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/909,128.
[cited by applicant]
Communication of a Notice of Opposition Dated Dec. 11, 2018 From the European Patent Office Re. Application No. 13185969.6. (4 Pages).
[cited by applicant]
Communication Pursuant to Article 101(1) and Rule 81(2) to (3) EPC Dated Dec. 5, 2019 From the European Patent Office Re. Application No. 13185969.6. (4 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) Dated Jan. 15, 2020 From the European Patent Office Re. Application No. 18186556.9. (4 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EP Dated Feb. 21, 2022 From the European Patent Office Re. Application No. 17197313.4. (4 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Mar. 2, 2016 From the European Patent Office Re. Application No. 13185969.6.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Apr. 11, 2017 From the European Patent Office Re. Application No. 06766237.9. (5 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Jul. 23, 2013 From the European Patent Office Re. Application No. 07790025.6.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Sep. 25, 2015 From the European Patent Office Re. Application No. 07790025.6.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Mar. 27, 2017 From the European Patent Office Re. Application No. 13185969.6. (4 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Jul. 28, 2014 From the European Patent Office Re. Application No. 07790025.6.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Sep. 28, 2011 From the European Patent Office Re. Application No. 07790025.6.
[cited by applicant]
Communication Pursuant to Rule 70(2) and 70a(2) EPC and Reference to Rule 39(1) EPC Dated Oct. 20, 2014 From the European Patent Office Re. Application No. 13185969.6.
[cited by applicant]
Communication Pursuant to Rules 70(2) and 70a(2) EPC Dated Aug. 10, 2010 From the European Patent Office Re. Application No. 06766237.9.
[cited by applicant]
Communication Pursuant to Rules 70(2) and 70a(2) EPC of May 25, 2011 From the European Patent Office Re. Application No. 06766237.9.
[cited by applicant]
Communication Pursuant to Rules 70(2) and 70a(20 EPC and Reference to Rule 39(1) EPC Dated Aug. 6, 2018 From the European Patent Office Re. Application No. 17197313.4. (2 Pages).
[cited by applicant]
Communication Relating to the Results of the Partial International Search Dated Jan. 9, 2008 From the International Searching Authority Re.: Application No. PCT/IL2007/000970.
[cited by applicant]
Communication Under Rule 71(3) EPC Dated May 2, 2016 From the European Patent Office Re. Application No. 07790025.6.
[cited by applicant]
Communication Under Rule 71(3) EPC Dated Apr. 12, 2018 From the European Patent Office Re. Application No. 13185969.6. (7 Pages).
[cited by applicant]
European Search Report and the European Search Opinion Dated Sep. 12, 2014 From the European Patent Office Re. Application No. 13185969.6.
[cited by applicant]
European Search Report and the European Search Opinion Dated Nov. 13, 2018 From the European Patent Office Re. Application No. 18186556.9. (10 Pages).
[cited by applicant]
European Search Report and the European Search Opinion Dated Apr. 18, 2018 From the European Patent Office Re. Application No. 17197313.4. (7 Pages).
[cited by applicant]
Examination Report Dated Mar. 27, 2012 From the Intellectual Property Office of Singapore Issued by the Austrian Patent Office, Service and Information Center (TRF) on Feb. 20, 2012 Re. Application No. 200801730-3.
[cited by applicant]
Examination Report Dated Jan. 30, 2014 From the Intellectual Property Office of Singapore Issued by the Austrian Patent Office Re. Application No. 201200039-4.
[cited by applicant]
Examiner's Report Dated Jan. 27, 2012 From the Australian Government IP Australia Re. Application No. 2006286149.
[cited by applicant]
Examiner's Report Dated Aug. 29, 2011 From the Australian Government IP Australia Re. Application No. 2006286149.
[cited by applicant]
Final Official Action Dated Aug. 20, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 15/814,432. (5 pages).
[cited by applicant]
International Preliminary Report on Patentability Dated Feb. 3, 2009 From the International Bureau of WIPO Re. Application No. PCT/IL2007/000970.
[cited by applicant]
International Preliminary Report on Patentability Dated Apr. 9, 2009 From the International Bureau of WIPO Re. Application No. PCT/IL2006/000998.
[cited by applicant]
International Search Report Dated Jun. 13, 2008 From the International Searching Authority Re. Application No. PCT/IL2007/000970.
[cited by applicant]
International Searching Report and the Written Opinion Dated Jun. 4, 2008 From the International Searching Authority Re. Application No. PCT/IL2006/00998.
[cited by applicant]
Invitation to Remedy Deficiencies Pursuant to Rule 30(3) EPC / Rule 163(3) EPC Dated Nov. 26, 2013 From the European Patent Office Re. Application No. 13185969.6.
[cited by applicant]
Notice of Allowance Dated Feb. 1, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/991,077.
[cited by applicant]
Notice Of Allowance Dated Apr. 5, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/209,776. (10 pages).
[cited by applicant]
Notice of Allowance Dated Aug. 5, 2022 from US Patent and Trademark Office Re. U.S. Appl. No. 16/454,168. (6 pages).
[cited by applicant]
Notice of Allowance Dated Oct. 9, 2014 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/309,817.
[cited by applicant]
Notice Of Allowance Dated Mar. 14, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/909,128.
[cited by applicant]
Notice of Allowance Dated Dec. 18, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/814,432. (5 Pages).
[cited by applicant]
Notice of Allowance Dated Jan. 26, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/309,817.
[cited by applicant]
Notice Of Allowance Dated Jul. 28, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/720,853. (9 pages).
[cited by applicant]
Notice of Non-Compliant Amendment Dated Sep. 2, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/909,128.
[cited by applicant]
Official Action Dated Sep. 5, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/209,776. (19 pages).
[cited by applicant]
Official Action Dated Apr. 6, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/814,432. (14 Pages).
[cited by applicant]
Official Action Dated Dec. 6, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/309,817.
[cited by applicant]
Official Action Dated May 9, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/309,817.
[cited by applicant]
Official Action Dated Aug. 11, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/991,077.
[cited by applicant]
Official Action Dated Jan. 12, 2022 from US Patent and Trademark Office Re. U.S. Appl. No. 16/454,168. (44 pages).
[cited by applicant]
Official Action Dated Mar. 13, 2012 From the US PAtent and Trademark Office Re. U.S. Appl. No. 11/991,077.
[cited by applicant]
Official Action Dated Feb. 14, 2014 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/309,817.
[cited by applicant]
Official Action Dated Oct. 15, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/909,128.
[cited by applicant]
Official Action Dated Apr. 17, 2017 from the US Patent and Trademark Office Re. U.S. Appl. No. 14/720,853. (7 pages).
[cited by applicant]
Official Action Dated Oct. 18, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/309,817.
[cited by applicant]
Official Action Dated Mar. 22, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/209,776. (97 pages).
[cited by applicant]
Official Action Dated Oct. 24, 2012 From the US PAtent and Trademark Office Re. U.S. Appl. No. 11/991,077.
[cited by applicant]
Official Action Dated May 25, 2011 From the US PAtent and Trademark Office Re. U.S. Appl. No. 11/991,077.
[cited by applicant]
Official Action Dated Aug. 26, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/720,853.
[cited by applicant]
Official Action Dated Mar. 26, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/309,817.
[cited by applicant]
Official Action Dated Sep. 26, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/814,432. (33 pages).
[cited by applicant]
Partial European Search Report Dated Mar. 20, 2014 From the European Patent Office Re. Application No. 13185969.6.
[cited by applicant]
Patent Examination Report Dated Jan. 15, 2014 From the Australian Government, IP Australia Re. Application No. 2012262726.
[cited by applicant]
Patent Examination Report Dated Aug. 22, 2014 From the Australian Government, IP Australia Re. Application No. 2012262726.
[cited by applicant]
Patent Examination Report Dated Nov. 25, 2016 From the Australian Government, IP Australia Re. Application No. 2015203310. (4 Pages).
[cited by applicant]
Response Dated Jan. 2, 2012 to Second Written Opinion of Aug. 5, 2011 From the Austrian Patent Office on Behalf of the Intellectual Property Office of Singapore Re. Application No. 200801730-3.
[cited by applicant]
Response Dated Feb. 8, 2011 to Communication Pursuant to Rules 70(2) and 70a(2) EPC of Aug. 10, 2010 From the European Patent Office Re. Application No. 06766237.9.
[cited by applicant]
Response Dated Nov. 14, 2011 to Official Action of Aug. 11, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/991,077.
[cited by applicant]
Response Dated Dec. 23, 2010 to Communication Pursuant to Rules 70(2) and 70a(2) EPC of Aug. 10, 2010 From the European Patent Office Re. Application No. 06766237.9.
[cited by applicant]
Response Dated Jun. 23, 2011 to Official Action of May 25, 2011 From the US PAtent and Trademark Office Re. U.S. Appl. No. 11/991,077.
[cited by applicant]
Response Dated Nov. 24, 2011 to Communication Pursuant to Rules 70(2) and 70a(2) EPC of May 25, 2011 From the European Patent Office Re. Application No. 06766237.9.
[cited by applicant]
Response Dated Dec. 28, 2011 to Examiner's Report of Aug. 29, 2011 From the Australian Government IP Australia Re. Application No. 2006286149.
[cited by applicant]
Restriction Official Action Dated Oct. 7, 2021 from US Patent and Trademark Office Re. U.S. Appl. No. 16/454,168. (9 pages).
[cited by applicant]
Restriction Official Action Dated Jun. 11, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/909,128.
[cited by applicant]
Restriction Official Action Dated Sep. 20, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/209,776.(7 pages).
[cited by applicant]
Search Report and Written Opinion Dated Apr. 3, 2013 From the Intellectual Property Office of Singapore Issued by the Austrian Patent Office on Mar. 1, 2013 Re. Application No. 201200039-4.
[cited by applicant]
Search Report and Written Opinion Dated Jan. 26, 2010 Received From the Intellectual Property Office of Singapore on Aug. 16, 2010 Issued by the Austrian Patent Office, Service and Information Center (TRF) Re. Applicati…
[cited by applicant]
Second Supplementary European Search Report and the European Search Opinion Dated Apr. 20, 2011 From the European Patent Office Re. Application No. 06766237.9.
[cited by applicant]
Second Written Opinion Dated Aug. 5, 2011 From the Austrian Patent Office on Behalf of the Intellectual Property Office of Singapore Re. Application No. 200801730-3.
[cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Jul. 23, 2010 From the European Patent Office Re. Application No. 06766237.9.
[cited by applicant]
Written Opinion Dated Jun. 13, 2008 From the International Searching Authority Re. Application No. PCT/IL2007/000970.
[cited by applicant]
Amit et al. “Clonally Derived Human Embryonic Stem Cell Lines Maintain Pluripotency and Proliferative Potential for Prolonged Periods of Culture”, Developmental Biology, 227: 271-278, 2000.
[cited by applicant]
Amit et al. “Dynamic Suspension Culture for Scalable Expansion of Undifferentiated Human Pluripotent Stem Cells”, Nature Protocols, XP008146753, 6(5): 572-579, May 1, 2011.
[cited by applicant]
Amit et al. “Feeder Layer- and Serum-Free Culture of Human Embryonic Stem Cells”, Biology of Reproduction, XP002466324, 70(3): 837-845, Jan. 1, 2004. Abstract, p. 837-838, ES Cell Culture.
[cited by applicant]
Amit et al. “Feeder-Free Culture of Human Embryonic Stem Cells”, Methods in Enzymology, XP009105807, 420(3): 37-49, Jan. 1, 2006.
[cited by applicant]
Amit et al. “Human Feeder Layers for Human Embryonic Stem Cells”, Biology of Reproduction, 68: 2150-2156, 2003.
[cited by applicant]
Amit et al. “Suspension Culture of Undifferentiated Human Embryonic and Induced Pluripotent Stem Cells”, Stem Cell Reviews and Reports, 6(2): 248-259, Apr. 30, 2010.
[cited by applicant]
Cheng et al. “Human Adult Marrow Cells Support Prolonged Expansion of Human Embryonic Stem Cells in Culture”, Stem Cells, 21: 131-142, 2003.
[cited by applicant]
Cowan et al. “Derivation of Embryonic Stem-Cell Lines From Human Blastocysts”, The New England Journal of Medicine, 350(13): 1353-1356, 2004.
[cited by applicant]
Daheron et al. “LIF/STAT3 Signaling Fails to Maintain Self-Renewal of Human Embryonic Stem Cells”, Stem Cells, 22: 770-778, 2004.
[cited by applicant]
GenBank GenBnak Overview, Printed from Website, 2, 2022.
[cited by applicant]
Hovatta et al. “A Culture System Using Human Foreskin Fibroblasts as Feeder Cells Allows Production of Human Embryonic Stem Cells”.
[cited by applicant]
Humphrey et al. “Maintenance of Pluripotency in Human Embryonic Stem Cells Is STAT3 Independent”, Stem Cells, XP002463152, 22(4): 522-530, Jan. 1, 2004.
[cited by applicant]
Klimanskaya et al. “Human Embryonic Stem Cells Derived Without Feeder Cells”, The Lancet, 365: 1636-1641, Mar. 7, 2005. p. 1636, Methods.
[cited by applicant]
Kollet et al. “The Soluble Interleukin-6 (IL-6) Receptor/IL-6 Fusion Protein Enhances In Vitro Maintenance and Proliferation of Human CD34+CD38−/Low Cells Capable of Repopulating Severe Combined Immunodeficiency Mice”, …
[cited by applicant]
Levenstein et al. “Basic FGF Support of Human Embryonic Stem Cell Self-Renewal”, Stem Cells, 24(3): 568-574, Mar. 2006.
[cited by applicant]
Ludwig et al. “Derivation of A Human Embryonic Stem Cells in Defined Conditions”, Nature Biotechnology, 24(2): 185-187, Feb. 2006.
[cited by applicant]
Mallon et al. “Toward Xeno-Free Culture of Human Embryonic Stem Cells”, International Journal of Biochemistry and Cell Biology, 38: 1063-1075, Jan. 23, 2006.
[cited by applicant]
Nichols et al. “Derivation of Germline Competent Embryonic Stem Cells With a Combination of Interleukin-6 and Soluble Interleukin-6 Receptor”, Experimental Cell Research, 215(1): 237-239, Nov. 1994.
[cited by applicant]
Niwa et al. “Self-Renewal of Pluripotent Embryonic Stem Cells Is Mediated via Activation of STAT3”, Genes & Development, 12: 2048-2060, 1998.
[cited by applicant]
Ueda et al. “Establishment of Rat Embryonic Stem Cells and Making of Chimera Rats”, PLoS one 3(7):2 e2800, 1-9, Jul. 2008.
[cited by applicant]
Van der Jeught et al. “Application of Small Molecules Favoring Naive Pluripotency During Human Embryonic Stem Cell Derivation”, Cellular Reprogramming, XP055224755, 17(3): 170-180, Jun. 1, 2015.
[cited by applicant]
Xu et al. “Basic Fibroblast Growth Factor Supports Undifferentiated Human Embryonic Stem Cell Growth Without Conditioned Medium”, Stem Cells, 23: 315-323, 2005. Abstract, p. 316, hES Culture.
[cited by applicant]
Xu et al. “Feeder-Free Growth of Undifferentiated Human Embryonic Stem Cells”, Nature Biotechnology, XP002672078, 19(10): 971-974, Oct. 2001.
[cited by applicant]
Yamanishi et al. “Roles of Transforming Growth Factor Beta in Inhibition of Androgen-Induced Growth of Shionogi Carcinoma Cells in Serum-Free Medium”, Cancer Research, 50: 6179-6183, Oct. 1, 1990.
[cited by applicant]
Yoshida et al. “Maintenance of the Pluripotential Phenotype of Embryonic Stem Cells Through Direct Activation of GP130 Signalling Pathways”, Mechanisms of Development, 45: 163-171, 1994.
[cited by applicant]
Zhang et al. “Enhacement of Oligodendrocyte Differentiation from Murine Embryonic Stem Cells by an Activator of gp 130 Signaling”, Stem Cells, 22(3): 344-354, May 2004.
[cited by applicant]
Zur Nieden et al. “Embryonic Stem Cells Remain Highly Pluripotent Following Long Term Expansion as Aggregates in Suspension Bioreactors”, Journal of Biotechnology, 129: 421-432, 2007.
[cited by applicant]